Navigation Links
BioTrends Research Group, Inc. Recognized as One of Philadelphia's Fastest Growing Privately Held Companies
Date:10/27/2008

EXTON, Pa., Oct. 27 /PRNewswire/ -- BioTrends Research Group, Inc. was named one of the 2007 Top 100 fastest-growing, privately-held businesses in the Philadelphia region by the Philadelphia 100(R), a joint project of the Wharton Small Business Development Center, the Entrepreneurs' Forum of Greater Philadelphia, and the Philadelphia Business Journal. The rankings are based on verifiable revenue growth.

"This recognition is a testament to the uniqueness of our business model and the value that our reports and services provide to our clients," said Jennifer Robinson, founder and president of BioTrends.

BioTrends was founded in 2004 making this the first year that the company was eligible for nomination to the Philadelphia 100. BioTrends is a leader in providing specialized, syndicated market research in clinically complex, small to mid-size pharmaceutical markets.

For more information about BioTrends, please visit http://www.bio-trends.com.

Contact:

Jennifer Robinson

BioTrends Research Group, Inc.

610-363-3872


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
2. BioTrends Releases Quarterly TreatmentTrends(TM): Nephrology Report Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
3. New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists
4. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
6. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
7. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
8. Calvert Research and Auburn University Announce Joint Venture
9. Anti-Stem-Cell-Research Ad Ignores Facts
10. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
11. Researchers show how to stamp nanodevices with rubber molds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... media products engineered to radically streamline culture processes, minimize processing time, significantly ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") ... presented at the Company,s Annual and Special Meeting. ... take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, Calgary, ... of meeting and management information circular, containing the matters to ...
Breaking Biology Technology:
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... 2016 Not many of us realize that we spend ? of our ... need to do it well. Inadequate sleep levels have been found to lead to ... and even cancer. Maybe now is the best time to rethink how ... to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... BioDirection, a privately held medical device company ... detection of concussion and other traumatic brain injury (TBI), ... meeting with the U.S. Food and Drug Administration (FDA) ... During the meeting company representatives reviewed plans for clinical ... commencement of a planned pilot trial. ...
Breaking Biology News(10 mins):